戻る
Tivic Health Systems Inc (TIVC)価格
TIVC 株価推移チャート
TIVC 収入
Tivic Health Systems Inc
$0.85
3.37%
$0.02
終値： Feb 06, 16:00:00 GMT-5
$0.85
0%
$0
アフターマーケット：Feb 06, 20:00:00 GMT-5
最新の利益結果: Q2 '24
報告済み: 2024-08-14
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
TIVCの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Tivic Health Systems Inc TIVCの前四半期の収益はどうでしたか？
Tivic Health Systems Incの収益見積もりはいくらですか？
Tivic Health Systems Incの収益品質スコアはどれくらいですか？
Tivic Health Systems Incはいつ収益を報告しますか？
Tivic Health Systems Incの予想収益はいくらですか？
Tivic Health Systems Incは収益予想を上回りましたか？
主要データ
前終値
$0.8301
始値
$0.8
当日レンジ
$0.78 - $0.893
52週レンジ
$0.78 - $15.64
取引高
88.7K
平均取引高
910.2K
1株当たり利益(TTM)
-9.87
配当利回り
--
時価総額
$1.5M
TIVCとは何ですか？
Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company is headquartered in Fremont, California and currently employs 7 full-time employees. The company went IPO on 2021-11-11. The Company’s biopharma program is focused on advancing its drug product candidate, Entolimod, into manufacturing, conducting process validation utilizing the output of such manufacturing with the intent of selling the biologic compounds either inside or outside the United States. The Company’s bioelectronic program is focused on developing non-invasive medical devices that influence biologic functions associated with various diseases and conditions. The company has an over-the-counter device, ClearUP, that treats sinus pain and pressure. The Company’s Toll-like Receptor 5 (TLR5) program’s lead product candidate is the late-stage TLR5 agonist, Entolimod, to treat acute radiation syndrome (ARS) and for remediating side effects of medical radiation and chemotherapy. The firm offers contract development and manufacturing organization through its subsidiary Velocity Bioworks, Inc.